Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines
Toro-Salazar OH, Lee JH, Zellars KN, Perreault PE, Mason KC, Wang Z, Hor KN, Gillan E, Zeiss CJ, Gatti DM, Davey BT, Kutty S, Liang BT, Spinale FG. Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines. Cardio-Oncology 2018, 4: 4. PMID: 29900007, PMCID: PMC5995570, DOI: 10.1186/s40959-018-0030-5.Peer-Reviewed Original ResearchLow cumulative dosesBiomarker profilesCumulative dosesSerial cardiac magnetic resonance imagingResultsLeft ventricular ejection fractionCardiac magnetic resonance imagingAbnormal strain parametersSerum biomarker profilesAnti-inflammatory markersVentricular ejection fractionPediatric cancer survivorsPediatric cancer patientsFunctional imaging parametersPlasma biomarker profilesMagnetic resonance imagingAnthracycline doseAnthracycline dosesAnthracycline dosingLongitudinal strain magnitudeSubclinical dysfunctionAnthracycline treatmentEjection fractionPediatric patientsCancer survivorsInterleukin-10